Kyntra Bio (KYNB) Q3 2026 Earnings Call Transcript

Source The Motley Fool
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Monday, Nov. 16, 2026

CALL PARTICIPANTS

  • LifeSci Advisors - Gaia Shamis
  • Chief Executive Officer - Thane Wettig
  • Chief Financial Officer - David DeLucia
  • Chief Medical Officer - Dr. Carrie Brownstein
  • Vice President of Product Development - Carol Gaddum

TAKEAWAYS

  • Revenue -- $1.8 million, representing an increase from $1.1 million one year ago.
  • Net Income -- $0.2 million, or $0.04 per share, primarily driven by a $14 million gain from debt restructuring.
  • Cash and Liquidity -- $44.1 million in cash, cash equivalents, investments, and accounts receivable as of Sept. 30, 2026.
  • Operating Expense Savings -- Over $20 million across 2027 to 2028, resulting from the termination of the FG-3246 and FG-3180 program.
  • Royalty Obligation Reduction -- $60 million, following an amendment that lowered the maximum aggregate payment to NovaQuest Capital Management from $125 million to $65 million.
  • NovaQuest Upfront Payment -- $42.6 million, paid during the third quarter to reduce long-term royalty liabilities.
  • Phase 3 Initiation -- Q1 2027, contingent upon securing a strategic partnership or an external capital raise.
  • MATTERHORN High Transfusion Burden TI Rate -- 36% for patients on roxadustat versus 7% for those on placebo, achieving transfusion independence for at least 8 weeks.
  • ESA Refractory Response -- 31% for roxadustat-treated patients compared to 0% for the placebo group within the first 28 weeks of the MATTERHORN study.
  • Grade 3 Adverse Events (HTB Subgroup) -- 65% for roxadustat patients versus 27% for those on placebo, though treatment discontinuation rates remained similar at 22% and 20%, respectively.
  • Peak Sales Forecast -- $1 billion in the United States, based on an assessment conducted by ZS Associates.
  • MDS Patient Population -- 74,000 individuals in the United States, with 52,000 having lower-risk disease and 41,000 diagnosed with anemia.
  • Phase 3 Patient Enrollment -- 201 patients, randomized 2:1 between oral roxadustat and placebo.
  • Phase 3 Site Count -- 100 to 110 sites, with an expected enrollment period of 24 months.
  • Interim Analysis Timeline -- H2 2028, scheduled once 50% of patients complete 24 weeks of treatment.
  • Internal Rate of Return -- Over 26%, generated by the execution of the amended royalty financing agreement.
  • Phase 1 rPFS -- 8.7 months, reported for the FG-3246 program in a heavily pretreated population before the Phase 2 termination.
  • Phase 2 rPFS Target -- 10 months, which management stated was the minimum threshold required to continue development of the FG-3246 asset.
  • Cash Runway -- Into 2028, facilitating continued progress toward the initiation of the roxadustat Phase 3 trial.
  • Astellas Revenue Sharing -- 50%, allocated from revenue in covered territories excluding Japan to fund the remaining $15 million royalty cap.
  • Hemoglobin Increase -- Approximately 1 g per deciliter from baseline, sustained through week 28 in roxadustat-treated patients.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Wettig noted that the path forward for prostate cancer assets is challenging because "recently disclosed competitive data indicates that the clinical bar is simply getting higher."
  • Brownstein warned that in myelodysplastic syndromes patients, there is a background "2%-3% risk of thrombotic and cardiovascular events overall."

SUMMARY

Kyntra Bio, Inc. (NASDAQ:KYNB) announced a strategic restructuring into a pure-play rare disease company following the termination of its Phase 2 oncology program. Management reported that the decision to end development of FG-3246 was based on interim efficacy results that failed to meet radiographic progression-free survival targets. The company stated that its primary focus is now the Phase 3 development of roxadustat for anemia in lower-risk myelodysplastic syndromes. Management indicated that the Phase 3 trial design is supported by post-hoc analysis of high transfusion burden patients and alignment with the FDA on dosing parameters.

  • CEO Wettig stated that achieving the radiographic progression-free survival target was difficult as "recently disclosed competitive data indicates that the clinical bar is simply getting higher."
  • Management reported that the FDA is aligned with a starting dose of 2.5 mg per kilogram and a maximum of 3.5 mg per kilogram for the Phase 3 trial, which was the same protocol used in previous studies.
  • The company expects to maintain an enrollment rate of 0.1 patient per site per month across 100 to 110 clinical sites for the upcoming Phase 3 trial.
  • Carol Gaddum stated that market research identified "particularly high unmet need for an oral option in the community setting" where elderly patients face mobility challenges.
  • CMO Brownstein indicated that potential prescribers "are used to taking care of patients who have thrombotic events and/or are at risk for thrombotic events" and do not consider these events a reason to withhold treatment.
  • Management indicated that roxadustat has potential for first-line adoption in ring sideroblast-negative patients because current market leader luspatercept has not demonstrated clinically differentiated efficacy in that segment.

INDUSTRY GLOSSARY

  • CTGF: Connective tissue growth factor, a protein involved in fibrotic disorders.
  • ESA: Erythropoiesis-stimulating agent, a common first-line treatment for anemia.
  • EVRENZO: The trade name for roxadustat in certain international territories.
  • HIF: Hypoxia-inducible factor, a protein that coordinates the body's response to low oxygen.
  • HTB: High transfusion burden, defined as requiring four or more red blood cell units in two consecutive 8-week periods.
  • LR-MDS: Lower-risk myelodysplastic syndromes, a group of bone marrow disorders.
  • mCRPC: Metastatic castration-resistant prostate cancer.
  • rPFS: Radiographic progression-free survival, a measure of how long a patient lives without their cancer worsening on imaging tests.
  • RS: Ring sideroblast, a specific type of abnormal red blood cell precursor.
  • TI: Transfusion independence, the ability of a patient to go for a specified period without requiring a blood transfusion.

Full Conference Call Transcript

Operator: I would now like to hand the call over to Gaia Shamis. Please, go ahead.

Gaia Shamis: Thank you, operator. Good afternoon, everyone. Thank you for joining today to discuss Kyntra Bio's third quarter 2026 financial and business results. I'm Gaia Shamis from LifeSci Advisors. Joining me on today's call are Thane Wettig, Chief Executive Officer, David DeLucia, Chief Financial Officer, Dr. Carrie Brownstein, Chief Medical Officer, and Carol Gaddum, Vice President of Product Development. Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about Kyntra Bio.

Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kyntra Bio's filing with the SEC, including our most recent Form 10-K and Form 10-Q.

Kyntra Bio does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. The press release reporting the company's financial results and business update and a webcast of today's conference call can be found on the investor section of Kyntra Bio website at www.kyntrabio.com. With that, I would like to turn the call over to CEO Thane Wettig. Thane?

Thane Wettig: Thank you, Gaia. Good afternoon, everyone, and welcome to our third quarter 2026 earnings call. On today's call, I will provide important updates on the company's transformation and the direction of Kyntra Bio moving forward, and then David DeLucia, our CFO, will review the financials, after which we will open the call for your questions. Turning to slide three, in the fourth quarter of 2026, the company completed a pre-planned interim analysis of the phase II monotherapy trial of FG-3246, an antibody drug conjugate targeting CD46 in metastatic castration-resistant prostate cancer, and FG-3180, a companion PET imaging agent.

Unfortunately, based upon insufficient interim efficacy results that did not meet the threshold required to support continued development, we have made the decision to terminate the phase II study of FG-3246 and FG-3180. I would like to provide context underpinning our decision to terminate the program. In May of 2023, we entered into the license agreement with Fortis Therapeutics based on the potential of the CD46-targeted ADC and its companion PET imaging agent in mCRPC. In April of 2024, results from the phase I monotherapy study of FG-3246 demonstrated a median radiographic progression-free survival, or rPFS, of 8.7 months in the heavily pretreated population.

Our subsequent phase II monotherapy study was designed with the intention to determine whether we could improve upon those results, with a target of at least 10 months of median rPFS at final analysis, a target that was based not only on currently available therapies, but also based on data from products in development. Following the review of data from the planned interim analysis, the efficacy findings do not support continuing to advance the program. Not only do the data point to a challenging path forward, achieving the minimum of 10 months of median rPFS in both an all-comers population and in a CD46-enriched population, recently disclosed competitive data indicates that the clinical bar is simply getting higher.

We therefore made the decision to terminate the development of FG-3246 and FG-3180. As a result of this decision, the company is returning the asset to Fortis and has commenced wind-down activities. In addition, we will save approximately $20 million in planned operating expenses across 2027 and 2028. Clearly, this was not the outcome we had hoped for, and on behalf of Kyntra Bio, I would like to extend our sincere gratitude to the patients and their families, clinical investigators, their research teams, and site personnel, whose commitment and participation made this study possible.

Turning to slide four, we highlight our evolution into a pure-play rare disease company focused on the phase III development of roxadustat for patients with anemia associated with lower-risk myelodysplastic syndrome and high red blood cell transfusion burden, or HTB. Our phase III strategy is informed by the post-hoc results from the MATTERHORN study in the high transfusion burden population and reinforced by input from KOLs and a productive engagement with the FDA on the phase III study design. We believe that there is a substantial unmet need for a new treatment with a novel mechanism of action and oral route of administration that can demonstrate efficacy across the broad spectrum of patients suffering from anemia due to lower-risk MDS.

Additionally, we have transformed the company's balance sheet with the amendment of our NovaQuest royalty financing agreement, which reduced our maximum payment obligation by $60 million and lowered our remaining royalty-backed payment obligations to only $15 million. Our simplified capital structure and current cash balance of over $44 million provides the company a strong financial foundation and the resources to continue to prepare for the initiation of the roxadustat phase III development program. The termination of the FG-3246 and FG-3180 program enables us to concentrate our resources on the defined phase III development plan for roxadustat.

We are currently on track to initiate this study in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise. I will discuss our conviction behind this focus and review the clinical evidence and planned phase III trial design in subsequent slides. Moving on to the roxadustat lower-risk MDS program. Slide six highlights the prevalence and unmet need associated with lower-risk MDS. Approximately 74,000 people in the U.S. are living with MDS, including about 52,000 with lower-risk disease and roughly 41,000 patients diagnosed with anemia, the hallmark symptom and main driver of morbidity of this condition.

While additional therapies have become available over the past few years, patients who progress beyond first-line treatment continue to have limited options, as these treatments require in-office injections or infusions with responses that are often not durable. It stabilizes HIF-alpha, mimicking the body's natural response to low oxygen, leading to an increase in hemoglobin. Second, HIF activation stimulates red blood cell production by increasing endogenous erythropoietin, improving iron availability, and supporting red blood cell maturation. Third, and importantly, HIF activates GATA1, a master. Importantly, roxadustat has been approved in more than 40 countries for anemia associated with chronic kidney disease, demonstrating not only important hemoglobin response, but also significantly fewer transfusions in the CKD patient population.

In addition, over 1 million patients have been treated with roxadustat worldwide since its first approval in 2019, reinforcing its efficacy and safety profile. In the following slides, I will provide a detailed review of the post-hoc analysis of patients from our previous phase III MATTERHORN study, with a focus on patients with high transfusion burden using the International Working Group definition of four or more RBC units in two consecutive eight-week periods. We believe these results demonstrate roxadustat's potential as a safe and effective oral treatment option for patients with lower-risk MDS.

Slide eight highlights previously disclosed results in the high transfusion burden population from the MATTERHORN phase III trial, demonstrating that treatment with roxadustat led to transfusion independence in 36% of patients for at least eight straight weeks within the first 28 weeks of the trial, versus only 7% in the placebo group, with a nominal p-value of 0.041. These results are highly similar to the pivotal trial results from the two most recently approved therapies for anemia associated with lower-risk MDS. When we assessed eight-week RBC transfusion independence over 52 weeks in the high transfusion burden population, the corresponding rates were 45% for roxadustat and 13% for placebo, with a highly similar nominal p-value of 0.043.

The following slides provide additional supporting data of roxadustat's effect on this high transfusion burden population. Slide nine shows the potential durability of transfusion independence with treatment of roxadustat versus placebo over extended periods of time. In the high transfusion burden subgroup, 36% of roxadustat patients achieved at least 12 weeks of transfusion independence within 52 weeks, versus only 7% with placebo, and at least 16 weeks of transfusion independence within 52 weeks in 18% of roxadustat-treated patients versus 0% for placebo. On slide 10, when looking at hemoglobin levels over time, which is the underlying basis that enables transfusion independence to be achieved, there was a consistent and meaningful increase in hemoglobin in roxadustat-treated patients versus placebo.

Mean hemoglobin on roxadustat rose by approximately 1 g per deciliter from baseline and was sustained through week 28, while placebo remained near or slightly below baseline. These results reinforce the effect that roxadustat can have in the high transfusion burden patient population. We then further explored whether roxadustat has the potential to benefit patients regardless of ring sideroblast, or RS, status, which is shown on slide 11. In the MATTERHORN high transfusion burden patient group, we observed transfusion-independent responses in both RS-negative and RS-positive patients, 38% and 33%, respectively. These results were mimicked in the full analysis set, where 48% of RS-negative patients and 46% of RS-positive patients on roxadustat achieved eight-week RBC transfusion independence.

This is extremely important as we think about the substantial unmet need in RS-negative patients and the potential placement of roxadustat in the treatment paradigm. I will touch more on this later in the presentation. On slide 12, we assessed patients who had previously received ESA therapy. Among high transfusion burden patients categorized as ESA refractory, 31% of roxadustat-treated patients achieved at least eight weeks of transfusion independence within 28 weeks, compared with none of placebo-treated patients, with a nominal P-value of 0.040. As you can see, the roxadustat treatment effect versus placebo is more pronounced in the ESA refractory population than in the ESA-naive population.

We are highly encouraged by these results, given that ESA refractory high transfusion burden patients from the MATTERHORN study most closely mimic the inclusion criteria for our planned upcoming phase III study. Slide 13 highlights the efficacy of roxadustat in the high transfusion burden population by baseline EPO serum levels. Roxadustat achieved greater eight-week transfusion independence versus placebo in patients with baseline EPO serum levels both below 200 and above 200. This is consistent with the mechanism of action in treating anemia from lower-risk MDS that does not rely solely on EPO. Slide 14 summarizes the safety findings from MATTERHORN. In the overall study population, treatment-emergent adverse events occurred in a similar proportion of roxadustat and placebo patients.

When evaluating Grade 3 or higher events, treatment with roxadustat was associated with a higher incidence relative to placebo, 38% versus 21%, with no individual Grade 3 TEAE occurring in more than 5% of roxadustat-treated patients. Moving to slide 15, we took a closer look at the roxadustat safety profile in patients with high transfusion burden and believe it is consistent with the safety profile in the overall population. While Grade 3 or higher TEAEs were more frequent in roxadustat-treated patients compared to placebo at 65% versus 27%, the rate of treatment discontinuation due to adverse events were similar between the two groups at 22% for roxadustat and 20% for placebo.

Turning to slide 16, we believe roxadustat has the potential to offer a differentiated treatment option in lower-risk MDS, specifically for patients who progress beyond first-line therapy. While recent approvals have expanded treatment options, these therapies have limitations in efficacy, durability, safety, and treatment burden. Both luspatercept and imetelstat require an in-office injection or infusion, whereas roxadustat offers the convenience of oral administration three times per week. Notably, post-hoc results from the MATTERHORN study suggest the potential for meaningful transfusion independence in patients with high transfusion burden across both RS-positive and RS-negative disease.

This is especially relevant given luspatercept, the market-leading brand in the treatment of lower-risk MDS, has not demonstrated clinically differentiated efficacy in this RS-negative segment of the lower-risk MDS population and is not indicated for use in the second-line setting in RS-negative patients. Despite these limitations in the RS-negative population, luspatercept is forecasted to achieve revenue of more than $2.5 billion in the U.S. at the projected timing of a roxadustat approval and launch, highlighting the substantial commercial potential in lower-risk MDS. Primary research we have conducted with practicing hematologists and oncologists in the U.S. indicates that roxadustat has the potential to be a useful treatment option in both RS-positive and RS-negative patient segments.

While we can't make direct comparisons across clinical trials, we believe that demonstrating similar efficacy across the entire patient population could position roxadustat favorably in the treatment paradigm of lower-risk MDS. Moving to slide 17, as I mentioned, our target indication for roxadustat is for the treatment of anemia in patients with lower-risk MDS who are refractory to or ineligible for prior ESA treatment, where we believe roxadustat can raise the standard of care and address a significant unmet need across multiple treatment lines.

We believe we also have an opportunity to capture first-line share in the RS-negative setting, but it allows us to evaluate the potential to generate incremental data to further support the use of roxadustat in this frontline RS-negative population, bolstering the overall commercial opportunity of roxadustat. Turning now to the planned pivotal trial, our phase III strategy is informed by the post-hoc results from the MATTERHORN study in the high transfusion burden population and reinforced by input from KOLs and a productive engagement with the FDA on the phase III study design, which is shown on slide 18.

In this double-blind, placebo-controlled trial, patients with lower-risk MDS and high transfusion burden who are refractory to, intolerant of, or ineligible for ESA treatment will be randomized 2:1 to oral roxadustat versus placebo, each administered three times a week along with best supportive care. The primary endpoint is the rate of RBC transfusion independence over eight consecutive weeks during the first 24 weeks of the trial. Key secondary endpoints include 12, 16, and 24-week transfusion independence assessed over 48 weeks, as well as hematologic improvements and erythroid response, specifically the proportion of patients whose transfusion requirements are reduced by 50% or greater from baseline.

A planned interim analysis will be conducted once 50% of patients have completed 24 weeks of treatment or have discontinued treatment, which we expect will take place approximately 18 months after the initiation of the study. We have set the futility bar to a conditional power of less than 30%. If the roxadustat arm exceeds the futility bar, the study will progress through the primary analysis of 201 patients over 48 weeks. I will now review our development timeline for this program on slide 19. Our near-term priority remains the initiation of the phase III trial in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise.

Looking ahead, we are targeting the phase III interim analysis in the second half of 2028, followed by the primary analysis in the first half of 2030. To summarize the roxadustat opportunity in lower-risk MDS on slide 20, with a substantial unmet need, no oral therapeutic options on the market or in late-stage development, significant potential in the second-line setting, and importantly, in RS-negative patients, along with an orphan drug designation, we view roxadustat as a compelling commercial opportunity with blockbuster potential of approximately $1 billion in peak sales in the United States, a forecast that is informed by a rigorous external opportunity assessment conducted for us by ZS Associates.

With that, I will now turn the call over to Dave to discuss the company's financials. Dave?

David DeLucia: Thank you, Thane. I will begin with the amendment to our royalty financing agreement with NovaQuest Capital Management, summarized on slide 22. Under the amended agreement, the maximum aggregate payment obligation has been reduced from $125 million to $65 million, a decrease of $60 million. In the third quarter of 2026, we made an accelerated upfront payment of $42.6 million, bringing the total payments made to NovaQuest to $50 million. The remaining payments are capped at $15 million and will be funded from 50% of the revenue we receive from Astellas in the covered territories under the license agreement, excluding Japan.

Once the remaining cap is reached, the amended agreement will terminate, and we will retain subsequent EVRENZO royalty revenue in the applicable Astellas territories. Overall, the amendment significantly reduced our remaining long-term obligations under the original agreement and simplifies the remaining go-forward payments to NovaQuest associated with the Astellas royalties. The amendment was highly accretive to Kyntra Bio shareholders, generating an internal rate of return of over 26% based upon the new lowered forecasted obligations owed to NovaQuest. Now, turning to our financial results for the third quarter. For the third quarter of 2026, total revenue was $1.8 million compared to $1.1 million for the same period in 2025.

Total operating costs and expenses for the third quarter of 2026 were $14.6 million compared to $6.5 million for the third quarter of 2025. R&D expenses for the third quarter of 2026 were $8.3 million compared to $1.2 million in the third quarter of 2025. SG&A expenses for the third quarter of 2026 were $5.8 million compared to $5.3 million in the third quarter of 2025. As a result of the termination of the phase II study of FG-3246 and FG-3180, we are now forecasting a reduction of over $20 million in operating expenses across 2027 and 2028.

During the third quarter of 2026, we recorded a net income from continuing operations of $0.2 million, or $0.04 net income per basic and diluted share, compared to a net loss of $13.1 million, or $3.25 net loss per basic and diluted share one year ago. This was driven by a $14 million gain on debt restructuring from the execution of the amendment to our royalty financing agreement with NovaQuest. Now shifting towards cash. As of September 30th, we reported $44.1 million in cash equivalents, investments, and accounts receivable.

Due to the termination of the FG-3246 and FG-3180 program, we now expect the company to have a cash runway into 2028, enabling us to continue to progress roxadustat towards a phase III trial initiation next quarter. We continue to have ongoing discussions with both strategic partners and external capital providers for the funding of the roxadustat phase III trial. Thank you, and I will now turn the call back over to Thane.

Thane Wettig: Thank you, Dave. We enter the final months of 2026 with a sharpened focus and strong momentum. Our immediate priority is the completion of the funding process for the phase III trial of roxadustat and the subsequent initiation of the study planned in the first quarter of next year. With that, I would like to now turn the call over to the operator for Q&A.

Operator: As a reminder, to ask a question, you will need to press star one on your telephone. To remove yourself from the queue, you may press star one again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Michael King of Rodman & Renshaw. Please go ahead, Michael.

Michael King: Hi. Good afternoon, guys. Thanks for taking the questions. A couple of questions. First on FG-3246. Thane, do you guys plan on presenting any data of the results, or we just should forget that? I am just wondering if there were any clues from the radiolabeled version to help us understand whether CD46 was just a matter of lack of expression of the antigen, or is it possible there were some high-expressor patients that did better? I do not know if you can offer any color on those topics.

Thane Wettig: Yeah. Thanks, Mike, for your questions. First, in terms of disclosure, yeah, we will ensure that we work with Rahul Aggarwal, who is the PI at UCSF, regarding disclosure. I am sure that results will be disclosed in some form at some point in time. I cannot exactly say in what form or when, but we think this is important information for people to see, and I know that Dr. Aggarwal feels the same way. In terms of on any clues related to CD46 expression, I am going to ask Carol to handle that one, and then, if needed, pass it over to Carrie for additional comments. Carol?

Carol Gaddum: Thank you for the question. At this point, we have not analyzed the CD46 expression data. However, given the activity that we have seen in the all-comers population, it will not support continuous development. But that data is not available at this point in time. Passing on to Carrie for any additions.

Carrie Brownstein: Yeah, hi. Not too much extra. We are going to continue to look at that data. I do think, as Thane pointed out, it is important that we analyze it and understand. But as Carol mentioned, the data overall just was not enough to support further investment.

Michael King: Okay, fair enough. Second question is on ROX. I am just wondering, I know there is a substantial database of safety and efficacy in the dialysis population, but in lower-risk MDS, the post-hoc numbers are fairly small. If you look at that relative to your current capital position, does it set up this tension that you are going to run into when you are in discussions with a potential partner or other funding source regarding that fact?

Is it going to make your discussions a challenge, or would you actually just consider maybe running a small sort of introductory or preliminary study to get some greater efficacy, even if it is a single-arm open-label study to bolster the efficacy argument for ROX? I hope that wasn't too convoluted, but I think you know where I am going.

Thane Wettig: No, I know where you are going, Mike, and I will start it off, and then I will hand it over to Carrie. Just before Carrie takes over, just FYI, because I am not sure how broadly she has been introduced, Carrie actually was the Vice President and the head of the myeloid group at Celgene during the development of luspatercept. Not only does she know a tremendous amount about lower-risk MDS and drug development in the space, but we are really fortunate to have her as part of the team. In terms of getting at your question, Mike, I think that there are a couple of ways that one could go.

One could perhaps take a step back and do what you are suggesting. I think that then comes, well, at a cost of time and money. We think we have got a pretty important advantage being the only oral agent that has the potential to be in late-stage development. There are a couple of other oral agents that are entering phase II, so we would have, let us say, a two-to-three-year head start on them. I think that we have got enough data, honestly, even though you referenced that it is in a small subgroup.

I think that the way the data all hangs together, whether it be high transfusion burden patient population, the ESA refractory patient population, regardless of the EPO level, everything kind of hangs in there. We know that roxadustat raises hemoglobin, and we know that if you raise hemoglobin, then you are going to reduce the requirement for transfusions. We saw it in the CKD population, and we saw it in the subset analysis associated with the MATTERHORN trial.

If we were seeing kind of a data signal here that wasn't reinforced by another data signal, then I think we might say, "Hey, let us take a step back and maybe do some additional clinical work," perhaps, as you referenced, perhaps an open-label single-arm trial. I just don't think we would learn that much, honestly, relative to planning to go forward into the phase III trial. I can say that, without getting into specifics, that there are parties who look at our MATTERHORN data and are highly interested in what that data tells us. Carrie, why don't you take over from there?

Carrie Brownstein: Yeah, I mean, I think you said everything that needed to be said. I think that going back and doing another phase II to further bolster the data package that we have to support a phase III is one way to go. But I agree with Thane. Even though the data set is small, every way we look at it, as well as even if we include some of the other patients with slightly lower transfusion burden, it's pretty strong evidence for the drug to be working in this patient population. Again, I don't see us gaining too much extra from adding additional patients to the analysis.

Michael King: Okay, thanks for the call. I'll jump back in the queue.

Thane Wettig: Oh, thanks, Mike.

Michael King: Thank you.

Operator: Thank you. Our next question comes from the line of Jay Olson of Oppenheimer. Please go ahead, Jay.

Jay Olson: Oh, hey. Thanks for providing this update and taking the questions. With the phase III study initiation now planned for the first quarter next year, what operational work remains before you can get started? We appreciate the study timeline you shared. Can you just talk a little more about the rate of enrollment that investors should expect, and will the planned interim analysis be strictly a futility assessment, or would it also provide an opportunity to accelerate development? Then I had a follow-on, if I could, please.

Thane Wettig: Yeah. Thanks, Jay. Good to hear from you. I'll go ahead and kick it off, and then if I leave anything out, I'll ask Carrie and Carol to add in. In terms of the operational work that remains, the team has been really active over the past several months, either related to interactions with the agency regarding information requests, signing up the CRO, working with other vendors that obviously are critical to get a phase III trial off the ground. Really, the rate limiter for us is going to be the funding for the trial. So, the operational work has been largely complete, not entirely complete, but largely complete.

Then we're going to continue to do pieces of that as we go down the capital raise process. In terms of enrollment, what we are assuming is 201 patients. It's going to take 24 months to enroll. We would sign up anywhere from 100 to 110 sites. So, at steady state, we would assume that the enrollment rate is roughly one-tenth of one patient per site per month. We think we're being conservative. If you look at the MEDALIST trial for luspatercept, which Carrie was responsible for, they enrolled 220-plus patients in about 17 months. The MEDALIST had enrolled 180 patients in roughly 22 months or so.

So, given the much greater awareness of lower-risk MDS, the fact that we've got an oral option, the fact that patients could have been on luspatercept or roxadustat before going onto either rox or placebo in our trial, we think that there are a number of factors that would enable us to beat that 24-month enrollments period, but that's the current assumption. Then, Jay, the last question, what was that?

Jay Olson: Just related to the interim analysis and whether that is futility only, or could you use that to accelerate development?

Thane Wettig: Yeah, it is futility only. We will not be looking at it from a kind of an early stopping perspective. It is strictly futility.

Jay Olson: Okay, thank you. Thanks for all the additional color. If I could ask one follow-up, please.

Thane Wettig: I will just ask Carrie or Carol if there are any additional comments that they would like to add.

Carol Gaddum: No comment from my side.

Carrie Brownstein: No additional from me.

Thane Wettig: Okay. Yeah, go ahead, Jay.

Jay Olson: Your strategy highlights the advantages of an oral option across RS subtypes with potential expansion into first-line RS-negative disease. Based on your market research with physicians, where do you see the strongest initial adoption of roxadustat?

Thane Wettig: Yeah, great question. I am going to turn that over to Carol. She was the point person in working with ZS Associates a few months ago to do a pretty comprehensive opportunity assessment. We talked to 20 hematologists, oncologists in the U.S., a mix of academic and community-based physicians. We also spoke with five U.S.-based payers. Carol, why don't I turn it over to you?

Carol Gaddum: Thank you for the question. Initial strong adoption we certainly see in the 2L+ setting in RS-negative after ESA or luspatercept. There is a particularly high unmet need for an oral option in the community setting, where most of the treatment here is taking place, where this oral option could really benefit patients, especially the elderly ones with some mobility challenges. From there on, really an opportunity to expand more broadly across the 2L setting, agnostic of RS status, and then to Thane's earlier point, also into a frontline within selected patients where current treatment options aren't providing benefit.

Thane Wettig: Yeah, and maybe just one more comment on that, Jay. The preference share as stated by the clinicians in the research would say that we could kind of claw, carve out a high single-digit frontline share, primarily because of the fact that we are the only oral option available. There is a lot of value in that frontline share, just based upon how many patients stay in frontline therapy, and some of them don't end up progressing to second-line therapy.

What the physicians have told us over and over again is that based upon the health status of the patient, think about a 75-year-old with extreme anemia, as well as the proximity to a clinic, many of these patients have trouble coming into the clinic every three or four weeks for their injection or their infusion of luspatercept or MEDALIST. That is how one could envision then an interesting kind of frontline share that could then be supplemented with the additional data generation down the road.

Jay Olson: Thank you. That is super helpful. I really appreciate the comprehensive overview, and thanks for taking the questions.

Thane Wettig: No, thank you, Jay.

Operator: Thank you. Our next question comes from the line of Daniel Brims of Lake Street. Please go ahead, Daniel.

Daniel Brims: Thanks for taking the question. Sorry to see you need to do this pivot. The question I have is, when FDA had reviewed roxadustat before, they had pause with the thromboembolic events. With the increased number of the safety database from commercial use, have you figured out mitigation strategies around that, or have your discussions with the FDA when designing the phase III? Are they more comfortable with that AE profile?

Thane Wettig: Yeah. Thanks, Dan. Good to hear from you. I am going to start, and I am going to hand it over to Carrie, and then perhaps Carol after that. I am going to get into a little detail here, so apologies for that, but I think it is important context. I am going to touch on the CRL for CKD in the U.S. That CRL was exclusively around what the FDA believed was too rapid of a rate of rise of hemoglobin to too high of a target that then led to an imbalance in thromboembolic events.

When we approached the agency through the Type C meeting process, one of the most important questions we had to ask them, based upon their perspective of roxadustat or in the entire HIF class and thromboembolic events, were they comfortable with us starting another phase III trial in MDS using the same starting dose and maximum dose and similar titration algorithm as in the previous phase III MDS trial? Our feeling was that if they were really concerned about roxadustat and the hemoglobin rate of rise and thromboembolic events, that they would ask us to go back and do some additional dose-finding work, perhaps use a lower starting dose than we used in the previous MDS trial.

We asked very specifically, "Are you aligned with the 2.5 mg per kilogram starting dose and a maximum of 3.5 mg per kilogram dose as used in the previous MDS trial?" They came back and they said, "Unequivocally, yes." That was a really important outcome for us through that Type C process. I am going to ask, I think, Carrie to talk about the interaction with the agency and what we have done from an exclusion perspective to ensure that we are not only meeting the FDA's guidance here, but also making sure that we have got the opportunity to get a real good answer with respect to roxadustat for its efficacy and its safety profile. Carrie?

Carrie Brownstein: Thank you, Thane. Yeah, we had a really fruitful discussion with the FDA around this. As Thane pointed out, there was no objection to our starting dose and our titration schedule. Importantly, while we wanted to make sure that we do not see a significant risk of thrombotic and cardiovascular events, we did work closely with the agency to kind of tighten up some of the eligibility criteria and ensure we are not over-enrolling for patients who have a history of having multiple events or have a higher likelihood than your average MDS patient for an event. I think it is also important to point out just the background rate.

We already know that in MDS patients, there is a 2%-3% risk of thrombotic and cardiovascular events overall. And what we've seen from the MATTERHORN study is in line with what we've seen with other treatments in this patient population, including luspatercept, which showed an incidence of around 5%, and ESAs has seen even 10%. So, we expect that roxadustat will be in the range seen with other agents in this class, in this area for MDS, and also, these other ones are approved, and they're also recommended for use. So, I think we're in good shape there, and we're expecting to enroll nicely, and these additional eligibility will actually really be helpful for the study.

Thane Wettig: Okay. Carol, anything to add to that?

Carol Gaddum: No additions from my side.

Thane Wettig: Okay. Thanks, Carol. Dan, any other questions?

Daniel Brims: No. I mean, that's all I have right now.

Thane Wettig: Okay. Thank you.

Operator: Thank you. Our next question comes from the line of Michael Okunewitch of Maxim Group. Your line is open, Michael.

Michael Okunewitch: Hey, guys. Thank you for taking my questions today. I wanted to ask just a little bit about the decision to go after the high transfusion burden patients, and in particular, why it's a good target. Does this have more to do with the unmet need and the relative power needed to show a difference, or is there a scientific rationale for why roxa works better in this high transfusion burden segment?

Thane Wettig: No, thanks, Michael. Good to hear from you. I'll kick it off, and then I'll turn it over to Carrie. I think it's really informed by a couple of things. One is, if you look at the MATTERHORN trial, the reason the trial did not hit the primary endpoint is because of the high placebo response in the patients who required less than four units in the eight weeks leading up to the trial. It had a placebo response in that group that was extremely high, and it was a very consistent placebo response rate that was seen in the MEDALIST trial for luspatercept in patients who also required less than four units.

Luspatercept studied patients two to six in their MEDALIST trial in that second-line setting. They really got the maximum benefit in those patients who required at least four up to six. They had an extremely high placebo response. There's no scientific rationale for roxadustat in the HTB population. It's really a matter of making sure that we can conduct a trial that gives us the best chance of success from a clinical perspective that also is a very, very meaningful commercial opportunity as well. There's a substantial unmet need to get these patients who require four or more units over two consecutive eight-week periods of time down much lower than that or down to zero.

We know that when you look at that patient population, the placebo response is very low. It ranges anywhere from 3%, 4% up to 15%. What we've done is we've assumed a powering of our trial of a placebo response in that higher transfusion burden population of about 12%, knowing that we can drive a substantial difference in absolute terms of transfusion independence with roxadustat, just based upon what we learned from the MATTERHORN trial. Let me turn it over to Carrie, because I'm sure she has some additional points to add to that.

Carrie Brownstein: Yeah, no, Thane, I think you hit all of them. It's really yes and yes, in the sense that the four units or higher patients do have a higher unmet medical need. Also, it is a defined subgroup, which I think where the, if you look at the IWG criteria, the most recent ones, the four units or higher are considered the high transfusion burden, and the endpoints that are recommended for the different transfusion burden levels are different. From a just study design perspective, it makes sense to start at the four and use that patient population.

Thane Wettig: Yeah. Carol, do you have anything to add to that?

Carol Gaddum: No additions.

Thane Wettig: Okay. What else, Michael?

Michael Okunewitch: All right. I also did want to ask a little bit about the safety and the differential in the Grade 3s and the serious TEAEs between placebo and roxa, and why you expect that difference didn't really translate into a difference in treatment discontinuation. Do you think that suggests the actual unmet need here and the desire for an oral option that actually works?

Thane Wettig: Yeah. Carrie, I will pass that one over to you.

Carrie Brownstein: It is all of the above in the sense that, yes, I think patients who are higher transfusion burden just generally are usually had their disease a little bit longer. They have more underlying medical conditions and are not surprisingly having more SAEs and some more Grade 3s. The likelihood is twofold. One is, yes, they are more willing to stay on drug because there is a need and a desire for an oral option. I think also, too, is a lot of it probably has nothing to do with the drug, because they would have discontinued if it would have helped. I think that is really a combination of those factors.

Thane Wettig: Carrie, if you could also speak to, Michael, we did see some Grade 3 cardiovascular events as well. Carrie, speak to the discontinuation/continuation of study drug in the patient population.

Carrie Brownstein: Yeah, this is important, too, and this came up with the other cardiovascular question. We did see an imbalance in cardiovascular and thrombotic events in the study. What was interesting, again, it is a small n study, so even though there was imbalance, the total number of patients with a significant event were only eight. Of those eight, six of those eight actually paused, had their event, their thrombosis or whatever they were dealing with resolved, and they were actually able to restart medication without any additional problems. I think two of them actually stayed on drug and did not even pause while they were resolving their thrombotic events.

I think, again, it is a combination of both of these factors that, A, some of the events were probably not, had nothing to do with drug, and B, there is a desire to stay on drug and improve hemoglobin, decrease transfusions, despite having some issues, maybe having some issues due to the unmet need.

Thane Wettig: Yeah. Carrie, you are a hematologist oncologist. Can you speak to that specialty's ability to handle these types of adverse events in the clinic?

Carrie Brownstein: Yeah. I mean, this is bread and butter for these, I think, and this is a good difference potentially between when we were talking about the earlier CKD versus hem/onc. Hematologists who are dealing with this disease are used to taking care of patients who have thrombotic events and/or are at risk for thrombotic events. It is not something that the potential prescribers and PIs for our study are worried about. This is something that they can handle very easily and do not consider this a reason to not give drug to their patients.

Michael Okunewitch: All right. Thank you. Appreciate the additional clarity.

Thane Wettig: Yeah. Thank you, Michael, for the question.

Operator: Thank you. I would now like to turn the conference back to Thane Wettig for closing remarks, sir.

Thane Wettig: Yeah. Thanks, Latif, guys, and everybody, thank you for joining us for today's third quarter 2026 earnings call and for your continued interest in Kyntra Bio. Enjoy the rest of your day. Thanks, everyone.

Operator: This concludes today's conference call. Thank you for participating. You may now disconnect.

Should you buy stock in Kyntra Bio right now?

Before you buy stock in Kyntra Bio, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kyntra Bio wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
Author  TradingKey
8 hours ago
As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
placeholder
Gold Price Forecast: Gold Holds Key $3,850 Support, US October Retail Sales May Drive Rebound Toward $4,000As of the Asian session on Tuesday (November 17), gold (XAUUSD) maintained a weak rebound intraday today after recent continuous declines to a nearly one-year low, edging up 0.2% during t
Author  TradingKey
8 hours ago
As of the Asian session on Tuesday (November 17), gold (XAUUSD) maintained a weak rebound intraday today after recent continuous declines to a nearly one-year low, edging up 0.2% during t
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
12 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
placeholder
Australian Dollar declines below 0.6750 after RBA minutes, US Retail Sales data in focusThe AUD/USD pair trades with mild losses around 0.6730 during the early Asian session on Tuesday.
Author  FXStreet
16 hours ago
The AUD/USD pair trades with mild losses around 0.6730 during the early Asian session on Tuesday.
placeholder
Bitcoin Plunges 13% in a Week as Market Retreats to $60,000 LevelBitcoin plunged 13% over the past seven days as bullish defense lines crumbled in succession, officially kicking off the battle to defend the $60,000 mark.On November 16, following a viol
Author  TradingKey
Yesterday 10: 05
Bitcoin plunged 13% over the past seven days as bullish defense lines crumbled in succession, officially kicking off the battle to defend the $60,000 mark.On November 16, following a viol
goTop
quote